Search Bar & Filters
Found 2 Actively Recruiting clinical trials
Actively Recruiting
Healthy Volunteer
Researchers are studying XmAb942 in a combined Phase 1 and Phase 2 clinical trial involving healthy volunteers and participants with moderately to severely active ulcerative colitis UC. The study aims to evaluate the safety, how the body processes the drug, and how the drug affects the body in healthy individuals, followed by assessing XmAb942s effects in people with UC. This trial is randomized, double-blind, and placebo-controlled, designed to understand the treatments potential in UC. The study has three parts. Part A involves single ascending doses of XmAb942 or placebo given subcutaneously or intravenously to healthy volunteers. Part B includes multiple ascending doses administered intravenously to healthy volunteers. Part C enrolls participants with active UC to receive three different doses of XmAb942 or placebo during a 12-week induction period, followed by a 40-week maintenance period with a single XmAb942 dose, then a 36-week follow-up. Participants will attend scheduled visits for dosing and monitoring throughout the study. Researchers will assess safety by tracking adverse events in healthy volunteers and clinical remission in UC patients using the modified Mayo score and endoscopic evaluation. Additional blood tests will measure drug levels and effects. The total participation duration can extend up to about 72 weeks for UC patients, including treatment and follow-up periods.
Actively Recruiting
This research aims to compare two asthma inhalers that use different propellants in people with mild to moderate asthma. The study evaluates whether an investigational inhaler with a new climate-friendly propellant, HFA-152a, works as safely and effectively as inhalers using the existing HFA-134a propellant. This global Phase II study plans to enroll 468 patients in Europe, Latin America, Ukraine, South Africa, and the United Kingdom. Participants will use one of three inhaler treatments in a randomized, double-blind crossover design the investigational CHF5993 pMDI with HFA-152a, CHF5993 pMDI with HFA-134a, or CHF718 pMDI with HFA-134a. Each inhaler is taken as two puffs twice daily. The study compares lung function effects of these inhalers during treatment periods. During the trial, participants will be assessed for lung function through measurements like forced expiratory volume in 1 second FEV1 at baseline and after treatment. Researchers will monitor safety, treatment adherence, and asthma control over the study period. Participants undergo scheduled visits for these evaluations, with the study expected to complete in June 2027.